Results 131 to 140 of about 3,972 (148)
Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib [PDF]
European Journal of Pharmaceutics and Biopharmaceutics, 2022 INTRODUCTION: Larotrectinib is an FDA-approved oral small-molecule inhibitor for neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive cancer treatment.
Rolf W Sparidans +2 more
exaly +5 more sources
The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas [PDF]
Cancer, 2018 BACKGROUND: The highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK fusion cancers.
Steven G DuBois +2 more
exaly +2 more sources
Indirect Treatment Comparison of Larotrectinib versus Entrectinib in Treating Patients with TRK Gene Fusion Cancers [PDF]
Cancers, 2022 Information regarding the comparative efficacy of first‐generation receptor tyrosine kinase inhibitors is limited. This matching‐adjusted indirect comparison (MAIC) evaluated differences in efficacy and safety across larotrectinib and entrectinib trials.
Carsten Bokemeyer +2 more
exaly +2 more sources
Annals of Oncology, 2019 BACKGROUND: NTRK1, NTRK2 and NTRK3 gene fusions (NTRK gene fusions) occur in a range of adult cancers. Larotrectinib is a potent and highly selective ATP-competitive inhibitor of TRK kinases and has demonstrated activity in patients with tumours ...
Robert C Doebele, A F Farago, H A Burris
exaly +2 more sources
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children [PDF]
New England Journal of Medicine, 2018 BACKGROUND: Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors ...
Anna F Farago +2 more
exaly +3 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors
Neuro-Oncology, 2022Cornelis M van Tilburg +2 more
exaly
Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2023
Manal Alossaimi +2 more
exaly
Manal Alossaimi +2 more
exaly
Assignment of NMR data and Conformational analysis of larotrectinib and its precursors
Tetrahedron, 2021Deyong Ye, Xunlei Lv, Kuaile Lin
exaly